Protective Effects of Individual and Combined Low Dose Beta-Carotene and Metformin Treatments against High-Fat Diet-Induced Responses in Mice.
Adipocytes
/ metabolism
Adipose Tissue
/ metabolism
Adiposity
Animals
Blood Glucose
/ metabolism
Cell Size
Diet, High-Fat
Energy Metabolism
/ genetics
Fatty Acids
/ blood
Gene Expression Regulation
Insulin
/ blood
Male
Metformin
/ pharmacology
Mice, Inbred C57BL
Protective Agents
/ pharmacology
RNA, Messenger
/ genetics
Weight Gain
beta Carotene
/ pharmacology
carotenoids
cotherapy
obesity
phytochemical
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
14 Oct 2021
14 Oct 2021
Historique:
received:
29
07
2021
revised:
24
09
2021
accepted:
13
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
18
11
2021
Statut:
epublish
Résumé
Anti-obesity activity has been reported for beta-carotene (BC) supplementation at high doses and metformin (MET). We studied whether BC treatment at a closer to dietary dose and MET treatment at a lower than therapeutic dose are effective in ameliorating unwanted effects of an obesogenic diet and whether their combination is advantageous. Obesity-prone mice were challenged with a high-fat diet (HFD, 45% energy as fat) for 4 weeks while receiving a placebo or being treated orally with BC (3 mg/kg/day), MET (100 mg/kg/day), or their combination (BC+MET); a fifth group received a placebo and was kept on a normal-fat diet (10% energy as fat). HFD-induced increases in body weight gain and inguinal white adipose tissue (WAT) adipocyte size were attenuated maximally or selectively in the BC+MET group, in which a redistribution towards smaller adipocytes was noted. Cumulative energy intake was unaffected, yet results suggested increased systemic energy expenditure and brown adipose tissue activation in the treated groups. Unwanted effects of HFD on glucose control and insulin sensitivity were attenuated in the treated groups, especially BC and BC+MET, in which hepatic lipid content was also decreased. Transcriptional analyses suggested effects on skeletal muscle and WAT metabolism could contribute to better responses to the HFD, especially in the MET and BC+MET groups. The results support the benefits of the BC+MET cotreatment.
Identifiants
pubmed: 34684608
pii: nu13103607
doi: 10.3390/nu13103607
pmc: PMC8538788
pii:
doi:
Substances chimiques
Blood Glucose
0
Fatty Acids
0
Insulin
0
Protective Agents
0
RNA, Messenger
0
beta Carotene
01YAE03M7J
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Mech Ageing Dev. 2015 Nov;151:2-12
pubmed: 25818235
Diabetes Obes Metab. 2018 Sep;20(9):2264-2273
pubmed: 29752759
Curr Obes Rep. 2019 Jun;8(2):156-164
pubmed: 30874963
FASEB J. 2008 Mar;22(3):659-61
pubmed: 17942826
Cell Rep. 2019 Mar 12;26(11):2849-2858.e4
pubmed: 30865877
Front Endocrinol (Lausanne). 2020 Sep 25;11:571659
pubmed: 33101206
Int J Obes Relat Metab Disord. 2000 May;24(5):639-46
pubmed: 10849588
Obesity (Silver Spring). 2008 Mar;16(3):585-91
pubmed: 18239600
Front Endocrinol (Lausanne). 2021 Feb 01;11:601627
pubmed: 33597924
Biochim Biophys Acta. 2005 May 30;1740(2):305-12
pubmed: 15893457
J Nutr. 1989 Apr;119(4):665-8
pubmed: 2703921
Pediatrics. 2021 Mar;147(3):
pubmed: 33608415
Genes Nutr. 2015 Sep;10(5):27
pubmed: 26143179
J Lipid Res. 2020 Nov;61(11):1491-1503
pubmed: 32963037
J Nutr Biochem. 2021 Sep;95:108770
pubmed: 34000411
Exp Mol Med. 2018 Jan 26;50(1):e432
pubmed: 29371695
J Clin Endocrinol Metab. 2001 Oct;86(10):4776-81
pubmed: 11600540
EMBO J. 2017 Jun 1;36(11):1543-1558
pubmed: 28348166
Res Pharm Sci. 2015 Jul-Aug;10(4):275-87
pubmed: 26600855
Biomed Pharmacother. 2019 Mar;111:1156-1165
pubmed: 30841429
Child Obes. 2020 Apr;16(3):174-191
pubmed: 32068434
Int J Mol Sci. 2018 Apr 10;19(4):
pubmed: 29642592
Crit Rev Food Sci Nutr. 2018 Apr 13;58(6):958-971
pubmed: 27830947
Int J Mol Sci. 2019 May 13;20(9):
pubmed: 31085992
J Nutr. 2008 Oct;138(10):1923-30
pubmed: 18806102
Eur J Pharmacol. 1993 Jun 15;246(1):67-71
pubmed: 8354343
Br J Nutr. 2009 Dec;102(11):1686-94
pubmed: 19631020
Mol Cell Endocrinol. 2017 Apr 15;445:95-108
pubmed: 27743993
Prog Lipid Res. 2018 Apr;70:62-93
pubmed: 29679619
Mol Nutr Food Res. 2013 Aug;57(8):1423-34
pubmed: 23413212
J Endocrinol. 2000 Sep;166(3):511-7
pubmed: 10974645
Am J Physiol Endocrinol Metab. 2015 Jan 15;308(2):E172-83
pubmed: 25406261
Biochim Biophys Acta. 2013 May;1831(5):986-1003
pubmed: 23454373
Endocr Rev. 2021 Jan 28;42(1):77-96
pubmed: 32897388
Br J Nutr. 2015 Mar 28;113(6):867-77
pubmed: 25744306
Diabetologia. 2017 Sep;60(9):1566-1576
pubmed: 28776081
J Endocrinol. 2017 Jun;233(3):329-340
pubmed: 28522731
J Nutr. 1999 Dec;129(12):2271-7
pubmed: 10573562
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Nov;1865(11):158676
pubmed: 32120014
PLoS One. 2011;6(6):e20644
pubmed: 21673813
Endocrinology. 2006 Nov;147(11):5325-32
pubmed: 16840543
J Clin Invest. 2011 Jan;121(1):96-105
pubmed: 21123942
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Nov;1865(11):158597
pubmed: 31904420
J Nutr. 2020 Aug 1;150(8):2023-2030
pubmed: 32433733
Biochem Pharmacol. 1993 Feb 24;45(4):971-3
pubmed: 8383971
Cell Physiol Biochem. 2010;25(6):657-66
pubmed: 20511711
Clin Lab. 2014;60(6):887-96
pubmed: 25016691
Arch Biochem Biophys. 2015 Apr 15;572:112-125
pubmed: 25721497
J Biol Chem. 2010 Sep 3;285(36):27891-9
pubmed: 20573961
PLoS One. 2017 Feb 3;12(2):e0171293
pubmed: 28158227
Nature. 2020 Feb;578(7795):444-448
pubmed: 31875646
Nutrients. 2019 Apr 13;11(4):
pubmed: 31013923
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Diabetes. 2014 Mar;63(3):880-91
pubmed: 24270984
J Clin Endocrinol Metab. 2017 Jun 1;102(6):1983-1990
pubmed: 28323947
Biochem J. 1996 Aug 1;317 ( Pt 3):827-33
pubmed: 8760369
Am J Med. 1997 Dec;103(6):491-7
pubmed: 9428832
Pharmaceuticals (Basel). 2020 Jul 06;13(7):
pubmed: 32640543
Am J Physiol Regul Integr Comp Physiol. 2011 Jan;300(1):R1-8
pubmed: 21048077
Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E182-9
pubmed: 16478780